EXACT Sciences Corporation (EXAS) : During the past 4 weeks, traders have been relatively bearish on EXACT Sciences Corporation (EXAS), hence the stock is down -3.04% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.35% relative to the S&P 500. The 4-week change in the price of the stock is -3.17% and the stock has fallen -2.87% in the past 1 week.
The stock has recorded a 20-day Moving Average of 5.95% and the 50-Day Moving Average is 15.52%.The 200 Day SMA reached 97.24%. Exact Sciences Corporation is up 150.87% in the last 3-month period. Year-to-Date the stock performance stands at 101.95%.
EXACT Sciences Corporation (NASDAQ:EXAS): After opening at $18.18, the stock dipped to an intraday low of $17.941 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $18.72 and the buying power remained strong till the end. The stock closed at $18.64 for the day, a gain of 2.45% for the day session. The total traded volume was 2,207,519. The stocks close on the previous trading day was $18.195.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.